Please assess the completion status of the following clinical trial:

Trial Title: Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Signed Informed Consent~Exclusion Criteria:~* Younger than 18 years~* Participation in another clinical study in the past 30 days~* Permanent intake of antimicrobial, antiviral, immune suppressive substances~* Surgical intervention in the 3 months prior to inclusion or planned surgery during period of observation~* Known diabetes melitus~* Known and treated atopy or asthma bronchiale~* Cystic fibrosis, bronchopulmonale dysplasia, COPD~* Known diseases of the immune system, degenerative illnesses (e.g. auto-immune disorders like AIDS or leukemia, myeloma)~* Known metabolic or resorptive disorders~* Known chronic liver diseases (chronic hepatitis, liver cirrhosis)~* Known chronic kidney insufficiency~* Serious health issues (reduced health status, autoimmune illness, tumorous illness)~* Known allergy to plants of compositae family (camomille, dandelion) or to any substances of the investigational product~* At inclusion known pregnancy or planned pregnancy during period of investigation (required: active contraception for women of childbearing year)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Formulation A (Type: EXPERIMENTAL): Echinacea purpurea alcoholic extract lozenges (novel formulation)
- Formulation B (Type: EXPERIMENTAL): Echinacea purpurea alcoholic extract spray (novel formulation)
- Formulation C (Type: ACTIVE_COMPARATOR): Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
- Formulation D (Type: ACTIVE_COMPARATOR): Echinacea purpurea alcoholic extract, drops (basic formulation, reference)

Based on this trial design, predict the completion outcome and termination type (if applicable).